

A father has spent a decade and $70 million developing a groundbreaking gene therapy to treat his daughter's ultra-rare disease, creating a potential roadmap for hundreds of other families.

His company has now treated 10 patients in clinical trials, pushing the boundaries of rare disease treatment.

Want to know more?